Avtor/Urednik		Popovič, Peter; Šurlan, Miloš; Kuhelj, Dimitrij
Naslov		Kemoembolizacija hepatoceličnega karcinoma
Prevedeni naslov		Chemoembolization of hepatocellular carcinoma
Tip		članek
Vir		In: Repše S, Stanisavljevič D, editors. Zbornik simpozija Kirurgija jeter in vranice; 2004; Ljubljana. Ljubljana: Kirurška šola, Klinični oddelek za obdominalno kirurgijo,
Leto izdaje		2004
Obseg		str. 79-91
Jezik		slo
Abstrakt		Background. Hepatocellular carcinoma (HCC) is a common, difficult to treat cancer. Current treatment are surgical resection and liver transplantation. In patients who are unsuitable candidates for surgery, local ablation therapies appear to be valid mainly for treatment of single neoplastic lesions smaller than 3-4 cm in diameter. Systemic chemotherapy is mostly inactive. The dual vascular supply of the liver affords a unique opportunity to explore intraarterial therapies for hepatocellular carcinoma. Chemoembolization is a well-established technique combining intraarterial chemotherapy (mytomicin) with Lipiodol and delivery of embolic agents (Ivalon, Biospherej. In this article authors describe the role of chemoembolization (TACE) in the management of HCC. A clear presentation of TACE indications and contraindications is given. A detailed description of the procedure, complications, therapeutic results and a postprocedure follow-up are given.
Deskriptorji		LIVER NEOPLASMS CHEMOEMBOLIZATION, THERAPEUTIC EMBOLIZATION, THERAPEUTIC PALLIATIVE CARE MITOMYCINS